john lechleiter. thank you for ginning us. >> my pleasure.let's start out with the broad question about the industry, because this really is sort of the sentiments for the year ahead. this has been a tremendous few years for biotech and pharma. can that momentum continue? are you optimistic about 2015? >> i'm optimistic about 2015 but then again, a few years ago when everybody wasn't so optimistic, i was. i think we're now seeing the outcomes from a lot of this great science, a lot of the new technologies that have evolved in the last several years. so i think it's quite promising for the industry not only in 2015, but in the longer term as well. >> and talking about eli lilly specifically, you guys have gone through a period of patent expiration. what are you most excited about in your pipeline of new products that's beginning to replace that revenue? >> as you said, in the last several years, we've lost the -- essentially seen the patents expire on four of our largest products. we're sort of coming out of that period now. we've kept a stead